The Disintegration and Dissolution of Nabumetone Dispersible Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Disintegration and Dissolution of Nabumetone Dispersible Tablets
Nabumetone was complexed with β-cyclodextrin, and a 23 factorial design was used to prepare dispersible tablets containing the drug or its complex.The authors analyzed the effects of complexation as well as the levels of ammonium bicarbonate and crospovidone on tablet wetting time (WT), disintegration time (DT), and percent dissolution efficiency at 60 min (%DE60).


Pharmaceutical Technology


Differential scanning calorimetry (DSC). Samples of the drug, β-CD, physical mixture, and the kneaded complex were taken in flat round-bottomed aluminum pans and heated in a temperature range of 50–300 C at a rate of 10 C per minute with nitrogen purging (50 mL/min) using alumina as the reference standard in a differential scanning calorimeter (model pyris-1, Perkin Elmer, LLC, Norwallk, CT).

Powder x-ray diffraction (PXRD). The diffraction studies of the drug, β-CD, physical mixture, and the kneaded complex were performed in a powder x-ray diffractometer with a vertical goniometer (model PW 1050/37, Philips, the Netherlands). PXRD patterns were recorded using monochromatic CuK a radiation with nickel filter at a voltage of 40 kV and a current of 20 mA between 5 and 308 2θ values.

Experimental design


Table I: Factors and their corresponding levels as per 23 factorial design*.
An eight-run 23 factorial design consisting of three factors at two levels was set up to produce porous rapidly dispersing tablets of nabumetone (15). The levels of ammonium bicarbonate (X1) and crospovidone (X2) were the numerical factors analyzed, whereas the effect of complexation (X3) was investigated as the categorical factor. The responses evaluated were the disintegration time (Y1), wetting time (Y2), and dissolution efficiency at 45 min (Y3). The selected factors and their corresponding levels as per the design are listed in Table I.

Tablet compression. A total of eight batches of dispersible tablets containing the drug either in the free or the precomplexed form were produced by a wet granulation procedure using varying amounts of ammonium bicarbonate and crospovidone (16). The raw materials were passed through sieve #100 (150 μm) before dry mixing. The mixtures of ammonium bicarbonate, crospovidone, mannitol, sodium saccharine, and drug or its complex were dry mixed for 15 min in a glass mortar and pestle to obtain a uniform blend. The powder blend was granulated for 5 min using a solution of poly(vinylpyrrolidone) K-30 in ethanol (10% w/v) and passed through sieve #22 (710 μm). The granules obtained were air dried and passed through the same sieve to break the lumps.


Table II: Composition of model formulations of nabumetone dispersible tablets prepared as per 23 factorial design.
The dried granules passing through sieve #22 (710 μm) and retained on sieve #44 (355 μm) were lubricated with magnesium stearate and talc in a plastic bag for 5 min. The lubricated granules were compressed to tablets on a rotary tablet press (model Rimek RSB-4 mini press, Karnavati Engineering, Ahmedabad, India) using 13-mm round, flat-faced bevelled-edge tablet B tooling. Each tablet weighing 650 mg contained 50 mg of the drug in the free or in the precomplexed form. The compressed tablets were dried in a vacuum oven (Lab model, Servewell Instruments, Bangalore, India) at 60 C to a constant weight. The composition of the different batches of tablets produced as per the 23 factorial design is shown in Table II.

Disintegration time was recorded following the Indian Pharmacopeia procedure in a USP XXIII disintegration tester (model ED-2L, Electrolab Ltd (I) Ltd., Mumbai) (17). One tablet was placed in each tube of the apparatus using distilled water maintained at 37 0.5 C as a disintegrating medium. A conventional method was used to measure the wetting time and capillarity of the orodispersible tablets (18). Wetting time was recorded at 25 C in triplicate by placing a tablet in a 6.5-cm Petri dish, which contained 10 mL of water.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here